Trelegy Ellipta 25 ug/1 (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 25 ug/1

Trelegy Ellipta 25 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Strength

25 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0887-14) / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta 25 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is often prescribed for individuals who require a combination of a corticosteroid, a long-acting beta-agonist, and a long-acting muscarinic antagonist for effective respiratory management.

Side Effects

Common effects of Trelegy Ellipta 25 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a taste alteration. These effects are generally mild and temporary, but persistent or severe reactions should be discussed with a healthcare provider.

Precautions & Warnings

Trelegy Ellipta 25 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as heart disease or severe asthma, should use this inhaler with caution. Always inform your healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

Trelegy Ellipta 25 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. Alcohol consumption should be avoided as it can exacerbate some side effects. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Trelegy Ellipta 25 ug/1 is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Trelegy Ellipta 25 ug/1 is administered via inhalation, typically once daily. Follow the instructions provided by your healthcare provider.

Common side effects may include throat irritation, headache, and a dry mouth. Persistent or severe reactions should be discussed with a healthcare provider.

Trelegy Ellipta 25 ug/1 may interact with other medications, so it is important to inform your healthcare provider about all medications you are taking.

Trelegy Ellipta 25 ug/1 should be used with caution in patients with certain medical conditions, such as heart disease or severe asthma.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.